Nanoscope Therapeutics to Move Corporate Headquarters to Dallas
Company focused on unique optogenetic gene therapy to treat blindness
DALLAS, Texas (August 16, 2022) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that it is moving its corporate headquarters to Trinity Towers, in the hub of the Dallas Medical District.
“Moving to Trinity Towers places us in the heart of the growing healthcare community in Dallas,” said Nanoscope Co-Founder and CEO, Sulagna Bhattacharya. “Rapid growth is expected for Nanoscope in 2023 and Trinity Towers provides an excellent space for our expanding team to collaborate.”
Nanoscope’s MCO-010 is an optogenetic therapy delivered as a one-time intravitreal eye injection in an office setting. The therapy uses proprietary vector and promoter technology to deliver the MCO transgene into retinal bipolar cells. These retinal cells become light sensitive, potentially enabling vision in normal light environments.
MCO-010 is currently being evaluated in two clinical trials in the US for the treatment of severe vision loss due to retinitis pigmentosa (RP) and due to Stargardt disease. The Phase 2b multi-center randomized RESTORE trial of MCO-010 for RP is fully enrolled and results are expected in Q1 2023. In addition, the Phase 2 STARLIGHT trial of MCO-010 for Stargardt disease is underway and 6-month data from this multi-center open label study are expected in Q1 2023.
About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in a Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for RP (NCT04945772) with top line data expected Q1 2023. The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.
Opus Biotech Communications